Inclusion Criteria:

- Males presented with a confirmed histological diagnosis of adenocarcinoma of the
prostate with evidence of metastases (including bone, lymph nodes, or other site)
radiologically or histologically documented and despite a serum testosterone ≤1.73
nmol/L (50 ng/dL) proving castration, evidence of biochemical progression of prostate
cancer, documented by a rise in PSA .

Exclusion Criteria:

- Radiotherapy or surgery or antiandrogens (except LHRH analogue) or bilateral
orchiectomy within the 30 days preceding Visit 1. Incompletely healed surgical
incision.

- Concomitant anticancer therapy other than surgical castration or continuous medical
castration.

- Biology restriction.

- Clinical significant cardiovascular event or presence of cardiac disease that in the
opinion of the Investigator increases the risk of ventricular arrhythmia.

- History of arrhythmia which is symptomatic or requires treatment (CTCAE grade 3),
symptomatic despite treatment, or asymptomatic sustained ventricular tachycardia.
Subjects with atrial fibrillation controlled on medication are permitted.

- Hypertension not controlled by medical therapy

- ECG /QTc prolongation

- Presence of left bundle branch block (LBBB).